Silverback Therapeutics (SBTX) to Present SBT6290 Preclinical Data at the AACR 2021 Annual Conference
- Wall St. opens lower as Netflix slides, virus cases rise
- Netflix (NFLX) Plunges Following Q1 Sub Miss, But One Analyst Sees Chance to Turn Bullish
- Oil prices drop as India's COVID-19 surge dents demand outlook
- Intuitive Surgical (ISRG) Q1 Beat Prompts Two Street Upgrades
- Dollar firm as COVID-19 resurgence dampens risk appetite
Get instant alerts when news breaks on your stocks. Claim your 1-week free trial to StreetInsider Premium here.
Silverback Therapeutics, Inc. (Nasdaq: SBTX) (“Silverback”), a clinical-stage biopharmaceutical company leveraging its proprietary ImmunoTAC technology platform to develop systemically delivered, tissue-targeted therapeutics for the treatment of cancer, chronic viral infections and other serious diseases, will present preclinical data on its second product candidate, SBT6290, at the American Association of Cancer Research (AACR) 2021 Annual Conference, taking place virtually April 10-15. The data highlight the ability of SBT6290, a systemically administered Nectin4-directed TLR8 ImmunoTAC product candidate, to selectively activate myeloid cells in the tumor microenvironment, a promising approach to overcome resistance mechanisms associated with most current immunotherapies.
“SBT6290 showcases the versatility of our ImmunoTAC platform and along with our lead program SBT6050, exemplifies our goal to target difficult-to-treat solid tumors subset by subset. We are building on learnings from SBT6050, leveraging the same TLR8 linker-payload, which is highly transferrable across different targeting antibodies,” said Valerie Odegard, Ph.D., president & chief scientific officer of Silverback Therapeutics. “These preclinical data show that SBT6290 activates human myeloid cells in a Nectin4-dependent manner and that a SBT6290 mouse surrogate confers single agent anti-tumor activity in preclinical studies. We will continue to evaluate SBT6290 in GLP toxicology studies and anticipate submitting an IND for this program in the fourth quarter of 2021.”
SBT6290 comprises a selective TLR8 agonist conjugated to a Nectin4-specific monoclonal antibody. Nectin4 is a cell surface adhesion molecule that is overexpressed in multiple solid tumor types including urothelial, triple negative breast, squamous cell head and neck, and non-small cell lung cancers, with limited expression in normal tissues.
The abstract is now available on the AACR Annual Meeting website. Details of the poster presentation are as follows:
Title: SBT6290, a Systemically Administered Nectin4-Directed TLR8 ImmunoTAC® Product Candidate, is Designed for Tumor-localized Activation of Myeloid Cells
Abstract Number: 1858
Session Category: Immunology
Session Title: Therapeutic Antibodies, Including Engineered Antibodies
Virtual Poster Session Date and Time: The poster will be made available on the AACR website and Silverback website on April 10, 2021 at 8:30 a.m. ET
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- TG Therapeutics (TGTX) Reports Launch of ULTRA-V Phase 3 Trial Evaluating the Triple Combination of UKONIQ (umbralisib)
- Medtronic (MDT) Receives U.S. FDA Approval for Pipeline™ Flex Embolization Device with Shield Technology
- Enzo Biochem's (ENZ) Universal AMPICOLLECT Used on GENFLEX Molecular Platform Cleared for Distribution by FDA Under Emergency Use Authorization
Create E-mail Alert Related CategoriesCorporate News, FDA
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!